Randomized, comparative study of interferon β-1a treatment regimens in MSHillel Panitch, Brian G. Weinshenker, Douglas S. Goodin et al.|Neurology|2002Cited by 633
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosisSergio E. Baranzini, Jorge R. Oksenberg, Joanne Wang et al.|Human Molecular Genetics|2008Cited by 479
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyPaul O’Connor, Timon Bogumil, Massimo Filippi et al.|The Lancet Neurology|2009Cited by 403
Mapping Multiple Sclerosis Susceptibility to the HLA-DR Locus in African AmericansJorge R. Oksenberg, Stephen L. Hauser, Lisa F. Barcellos et al.|The American Journal of Human Genetics|2004Cited by 345
HLA-DR2 Dose Effect on Susceptibility to Multiple Sclerosis and Influence on Disease CourseLisa F. Barcellos, Stephen L. Hauser, Jorge R. Oksenberg et al.|The American Journal of Human Genetics|2003Cited by 294